Gastrointestinal Cancer

Katrina S. Pedersen, MD, MS, shares updates in the treatment of gastrointestinal cancers, including biliary tract cancer and neuroendocrine tumors.

Riccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.

Rachna Shroff, MD, MS, FASCO, highlights the prominence of the EMERALD-1 study for patients with HCC.

Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.

Katrina S. Pedersen, MD, MS, details how the treatment of patients with gastrointestinal malignancies is evolving and notes notable trials as well as approvals.

SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

The FDA granted fast track designation to 9MW2821 for potential use in advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

The biologics license application for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer has been accepted by the FDA.

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Manish A. Shah, MD, discusses 5-year outcomes from phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy for advanced esophageal cancer.

Mechanism of action for liver-directed therapies in HCC are illustrated by Anne Covey, MD, an interventional radiologist.

Anthony El-Khoueiry, MD, opens the discussion by defining the current prevalence of hepatocellular carcinoma (HCC).

Jacob Shreve, MD, MS, highlights the intersection between artificial intelligence and personalized medicine, as well as its potential utility in gastrointestinal cancers.

Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.